Top Markets
Coin of the day
Hyloris Pharmaceuticals S.A. Hyloris Pharmaceuticals S.A.

Hyloris Pharmaceuticals S.A.

HYL
Kedudukan dalam Saham #19935
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and... Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
Harga Saham
$5.22
Modal Pasaran
$146.14M
Perubahan (1 hari)
-1.35%
Perubahan (1 tahun)
-32.16%
Negara
BE
Perdagangan Hyloris Pharmaceuticals S.A. (HYL)

Kategori

Hasil untuk Hyloris Pharmaceuticals S.A. (HYL)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Hyloris Pharmaceuticals S.A., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Hyloris Pharmaceuticals S.A. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH